Targeting the CD155-CD226 axis has emerged as a promising strategy for enhancing the response to anti-PD-1 therapy, as Bcl9-depleted or -inhibited colorectal cancer cells exhibit improved therapeutic sensitivity [60]. The gene discussed is BCL9; the disease is colorectal cancer.